Financial Performance - The company's revenue for Q1 2023 was ¥381,711,743.06, a decrease of 13.04% compared to ¥438,930,890.48 in the same period last year[5] - The net profit attributable to shareholders was -¥14,727,136.62, representing a significant decline of 1,771.59% from ¥881,027.17 in the previous year[5] - The net cash flow from operating activities was -¥33,451,158.01, a decrease of 833.79% compared to ¥4,558,700.20 in the same period last year[5] - The net loss for Q1 2023 was CNY 14,814,886.45, compared to a net profit of CNY 881,027.17 in Q1 2022, indicating a significant decline in profitability[25] - Total operating revenue for Q1 2023 was CNY 381,711,743.06, a decrease of 13.0% compared to CNY 438,930,890.48 in Q1 2022[24] - Total operating costs for Q1 2023 were CNY 401,308,232.65, down from CNY 438,824,743.38 in the previous year, reflecting a reduction of 8.5%[24] Assets and Liabilities - The company's total assets increased by 8.93% to ¥1,607,354,887.22 from ¥1,475,544,376.48 at the end of the previous year[5] - The company's total assets increased to CNY 1,607,354,887.22 in Q1 2023, up from CNY 1,475,544,376.48 in Q1 2022, representing a growth of 8.9%[23] - Total liabilities rose to CNY 1,256,696,034.23 in Q1 2023, compared to CNY 1,117,957,493.80 in the same period last year, marking an increase of 12.4%[23] - The company's equity attributable to shareholders decreased to CNY 350,746,659.28 in Q1 2023 from CNY 357,586,939.14 in Q1 2022, a decline of 1.9%[23] Cash Flow and Management - The company's cash and cash equivalents increased by 93.90% to ¥46,540,898.43 from ¥24,002,274.06 at the end of the previous year[9] - Cash and cash equivalents at the end of Q1 2023 stood at 8,906,465.49 CNY, down from 65,554,509.09 CNY at the end of Q1 2022, indicating a liquidity squeeze[27] - The total cash inflow from operating activities was 184,658,735.51 CNY, a decrease of 51.3% from 379,373,278.61 CNY in the previous year[26] - The company’s cash flow management strategies will be crucial in navigating the current financial challenges and ensuring future growth[27] Research and Development - Research and development expenses rose by 128.80% to ¥2,645,482.22, up from ¥1,156,239.90 in the previous year, indicating increased investment in R&D[11] - Research and development expenses for Q1 2023 were CNY 2,645,482.22, up from CNY 1,156,239.90 in Q1 2022, reflecting an increase of 128.5%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,050[15] - Jiangsu Suhua Group holds 9.18% of shares, totaling 34,334,137 shares[15] - Hainan Jinsui International Holdings holds 9.09% of shares, totaling 34,000,000 shares, with 17,000,000 shares pledged[15] - Wang Yu holds 8.99% of shares, totaling 33,610,001 shares, with 23,793,411 shares under restriction[15] Other Income and Expenses - The company recorded a significant increase in other income, which rose by 349.86% to ¥2,110,950.00 from ¥469,250.00 in the previous year, primarily due to increased government subsidies[11] - The company reported a significant increase in sales expenses, which rose to CNY 4,151,556.37 in Q1 2023 from CNY 3,505,957.89 in Q1 2022, an increase of 18.4%[24] Investment Activities - The company has paid CNY 93.7 million for the acquisition of Jiangxi Deshipu New Materials Co., with CNY 8.7 million remaining unpaid[18] - The company is negotiating to terminate the agreement for the acquisition of Jiangxi Deshipu due to significant uncertainties and risks[19] - The company has not yet completed the payment of USD 16 million equivalent for the equity transfer, affecting its control over the target company's assets[19] Credit and Impairment - The company recorded a credit impairment loss of CNY -7,250,716.90 in Q1 2023, contrasting with a gain of CNY 181,269.13 in Q1 2022, highlighting a deterioration in asset quality[24]

Business Strategy and Focus - Jiangsu Lanfeng Bio-chemical Co., Ltd. reported a strategic shift in its main business focus from "pharmaceutical health + agrochemical" to solely agrochemical products production and sales[22]. - The company has established a strategic development direction rooted in agricultural technology and new materials, relying on phosgene products[22]. - The company’s main business has been focused on the production and sales of agrochemical products since the end of 2020[22]. - The company has no plans for major asset restructuring or acquisitions in the near future[22]. - The company is focusing on product innovation and R&D to meet the growing demand for safe and environmentally friendly agricultural products[36]. - The company aims to expand its market presence by developing new formulations and technologies, establishing a comprehensive solution capability[39]. - The company is exploring capital strategies to overcome challenges and enhance core competitiveness, aiming to improve profitability[39]. Financial Performance - The company’s operating revenue for 2022 was ¥1,445,239,989.37, a slight increase of 0.09% compared to ¥1,443,932,144.80 in 2021[24]. - The net profit attributable to shareholders was -¥320,692,444.11, an improvement of 34.71% from -¥491,191,923.36 in the previous year[24]. - The net cash flow from operating activities was -¥64,335,908.57, a significant decline of 645.38% compared to ¥11,796,557.54 in 2021[24]. - The basic and diluted earnings per share were both -¥0.8576, showing a 40.44% improvement from -¥1.44 in 2021[24]. - Total assets decreased by 14.61% to ¥1,475,544,376.48 at the end of 2022, down from ¥1,727,949,962.51 at the end of 2021[24]. - The net assets attributable to shareholders fell by 46.36% to ¥357,586,939.14 from ¥666,636,974.20 in the previous year[24]. - The company reported a quarterly operating revenue of ¥206,849,421.89 in Q4 2022, a decrease compared to previous quarters[28]. - The company achieved a total revenue of CNY 1,445,239,989.37 in 2022, representing a slight increase of 0.09% compared to the previous year[57]. - The gross margin for 2022 was reported at 35%, showing a slight improvement from 33% in the previous year[86]. Market Conditions and Challenges - The company faced various risks including market competition, safety and environmental risks, exchange rate fluctuations, and raw material price changes[4]. - The company faced significant challenges in the agricultural chemical industry due to rising raw material prices and supply chain disruptions[35]. - The agricultural chemical market continues to be affected by the energy consumption control policies from Q4 2021 to Q3 2022, leading to significant challenges in production scheduling and inventory management[39]. - The company is exposed to exchange rate fluctuations, with nearly two-thirds of its agricultural chemical revenue coming from exports, and will implement strategies to mitigate this risk[103]. - The company is managing raw material price volatility risks by securing stable supply contracts and optimizing production processes to control costs[104]. Research and Development - The company has established a new research institute focused on strategic new materials, aiming to enhance innovation in environmental protection and high-performance materials[54]. - The company is focusing on developing new technologies, including continuous production processes for key products, to enhance production stability and reduce costs[70]. - Research and development expenses amounted to ¥11,651,282.22, reflecting a decrease of 9.80% compared to the previous year[69]. - The number of R&D personnel decreased by 18.28% from 93 in 2021 to 76 in 2022, with the proportion of R&D personnel in total employees dropping from 6.62% to 4.52%[71]. Environmental Compliance and Safety - The company adheres to various environmental standards, including the "Comprehensive Emission Standard for Air Pollutants" and "Soil Environmental Quality Standards"[159][160]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a commitment to compliance with environmental regulations[159]. - The company has implemented strict measures for hazardous waste storage, ensuring compliance with the "Hazardous Waste Storage Pollution Control Standard"[161]. - The company has conducted 1 city-level emergency drill and 1 company-level emergency drill for environmental incidents in 2022, along with 16 workshop-level drills[172]. - The company has established a comprehensive emergency response plan for environmental incidents, which has been filed with the relevant environmental authorities[172]. Governance and Management - The company governance structure complies with the relevant regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[114]. - The board of directors consists of 7 members, including 3 independent directors, and held 7 meetings during the reporting period[111]. - The company actively engages in investor relations management to enhance governance levels[108]. - The company has established a performance evaluation system for senior management, linking compensation to work performance to enhance accountability and operational efficiency[150]. - The company has implemented a comprehensive internal control system to ensure compliance with laws and regulations, enhancing operational transparency and protecting shareholder rights[153]. Shareholder Relations and Dividends - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the year[144]. - The company has established a cash dividend policy, distributing no less than 20% of the annual distributable profits in cash, ensuring returns for shareholders[176]. - The company has not proposed any cash dividend distribution plan during the reporting period despite having a positive profit available for distribution to shareholders[144]. Legal Matters and Disputes - The court ruled that Jiangsu Lanfeng must pay a total of CNY 3,058,210 for repair costs and CNY 92,080 for tree compensation to Meili Pulp Paper[194]. - Jiangsu Lanfeng has expressed dissatisfaction with the first-instance judgment and has appealed to the Intermediate People's Court of Zhongwei[194]. - The company has initiated legal proceedings against Wang Yu for failing to fulfill performance compensation commitments, with a claim amounting to CNY 55.02 million and penalties[195]. Future Outlook - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20%[125]. - Future guidance for 2023 includes a revenue target of 1.65 billion RMB, representing a growth rate of 10%[87]. - The company plans to launch three new pesticide products in 2023, aiming for a market share increase of 5%[87]. - Jiangsu Lanfeng is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 15% from this region by 2025[87].

Group 1: Company Development Plans - The company plans to operate in both pharmaceutical and pesticide sectors, with potential for external acquisitions to expand these businesses [1] - The focus will be on light asset development in the pesticide sector, while the pharmaceutical sector will adapt based on actual conditions [1] Group 2: Acquisition Progress - The acquisition of Ark Pharmaceutical is in progress, with the issuance already approved but awaiting formal approval from the CSRC [1] - Ark Pharmaceutical has around 200 sales personnel and covers provincial channels [1] Group 3: Financial Performance - The main reason for the company's loss in 2015 was due to Ningxia Bluefeng, which incurred a loss of approximately 60 million due to environmental rectification halting production [3] - The main plant reported a profit of over 14 million in the first nine months of 2015, with expectations for improvement in Q4 [3] - The company anticipates that the pesticide and pharmaceutical sectors will perform well in 2016, with Ark Pharmaceutical expected to achieve a performance commitment of approximately 90 million [4]

江苏蓝丰生物化工股份有限公司 证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √ 特定对象调研 □分析师会议 □媒体采访 □业绩说 \n明会 □新闻发布会 □路演活动 \n□现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 西南证券：陈铁林 医药行业分析师 | | 人员姓名 | | | 时间 | 2015.11.10 14:00 | | 地点 | 公司证券工作室 | | 上市公司接待人 员姓名 | 董事会秘书 陈康；证券事务代表 王楚 | | 投资者关系活动 | 1 、公司选择医药方向转型的原因 | | 主要内容介绍 | 农药行业具有周期性和季节性，抗风险能力弱，属于 ...

Group 1: Company Overview - Jiangsu Lanfeng Bio-chemical Co., Ltd. is listed with stock code 002513 and abbreviated as Lanfeng Biochemical [1] Group 2: Investor Relations Activities - The investor relations activity involved specific object research with participation from various investment firms, including Shanghai Zhuque Investment and Guohai Franklin Fund [2] - The meeting took place on December 29, 2015, from 10:00 to 12:00 at Suzhou Suhua Group's main conference room [3] Group 3: Business Development and Projections - In 2016, the company expects to restore normal production in Ningxia Lanfeng, stabilizing the supply of multi-fungicides and related intermediates, leading to no further losses [3] - The company anticipates strong orders for its product, Rhizocone, indicating a positive outlook for its pesticide business [3] - The company plans to enhance its existing pesticide products, reduce excess capacity, and develop new products to improve profitability [4] Group 4: Pharmaceutical Sector Focus - The pharmaceutical sector is prioritized due to its higher added value and better market stability, with plans to support Ark Pharmaceutical's growth and strengthen the research and production of pharmaceutical intermediates [4] - Ark Pharmaceutical is exploring innovative marketing models and patient relationship management to transition from a single product sales model to a comprehensive health service model [4] Group 5: Mergers and Acquisitions Strategy - The company aims to select excellent projects for collaboration and actively seek new profit growth points through its public platform [5] - The projected 20% performance growth in Ark Pharmaceutical's profit forecast is based on the aging population trend and the broad market prospects for its anti-dementia and anti-tumor products [5] - The company plans to maintain its controlling stake through participation in financing activities, ensuring that future acquisitions do not hinder its external development [5][6]

江苏蓝丰生物化工股份有限公司 证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | --- | |----------------|----------|---------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议□媒体采访 □业绩说明 | | | 类别 | | 会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 众悦资产 | 陈星颖 | | | 人员姓名 | 易融乐投 | 代艺榕 | | | | 华商基金 | 梁皓 | | | | 广证恒生 | 唐爱金 | | | | 国元证券 | 李艳荣 | | | | 国元证券 | 臧福江 | | | | 国元证券 | 金红 | | | | 中银国际 | 王军 | | | | 华泰证券 | 曹党合 | | | | 宝盈基金 | 陈金伟 | | | | 瀚信资产 | ...

江苏蓝丰生物化工股份有限公司 证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | --- | |----------------|-------|---------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议□媒体采访 □业绩说明 | | | 类别 | | 会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | | 本次参与人员均为自然人中小投资者 | | | | | 陈勇丽 李军 | | | | | 孙先卫 许先超 | | | | | 陈立军 张刚 | | | | | 王虎田 厚坡 | | | | | 鲍运喜 周玉皎 | | | 参与单位名称及 | | 周素皎 邵静 | | | 人员姓名 | | 陈柯锦 许晴 | | | | | 许卫 付艳芳 | | | | | 许增兰 陈永静 | | | | | 安志凌 戴宏勇 | | ...

江苏蓝丰生物化工股份有限公司 证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司投资者关系活动记录表 编号：2017-002 | --- | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议□媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 海通证券 基础化工行业研究员 李智 | | | 人员姓名 | | | | | 时间 | 2017.9.15 14:30--16:30 | | | | 地点 | 公司会议室 | | | | 上市公司 | 蓝丰生化董事会秘书 陈康 | | | | 接待人员姓名 | 证券事务代表 王楚 | | | | 投资者关系活动 | 1 | 、公司目前农化产品的 ...

Financial Performance - The company's revenue for Q3 2022 was ¥354,200,793.01, a decrease of 20.47% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥1,784,157.70, a decline of 93.79% year-on-year[4]. - Total operating revenue for the period reached ¥1,238,390,567.48, an increase of 14.1% compared to ¥1,085,671,226.21 in the previous period[17]. - The net profit for the period was ¥673,458.03, a significant recovery from a net loss of ¥42,229,317.91 in the same period last year[19]. - The basic and diluted earnings per share were both ¥0.002, compared to a loss per share of ¥0.1242 in the previous year[19]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥2,102,291,260.62, an increase of 21.66% from the end of the previous year[4]. - The company's total assets as of September 30, 2022, amount to ¥2,102,291,260.62, an increase from ¥1,727,949,962.51 at the beginning of the year[15]. - Current assets decreased to ¥495,797,583.81 from ¥546,039,989.40 at the beginning of the year[14]. - The total liabilities increased to ¥1,421,407,702.72, compared to ¥1,061,312,988.31 in the previous period, indicating a rise of 33.9%[16]. - The company's total liabilities increased by 112.03% to ¥486,209,362.19, primarily due to stock incentive plans and pending payments for equipment purchases[9]. Cash Flow - The cash flow from operating activities showed a net outflow of -¥52,841,683.43, representing a decrease of 191.30%[4]. - Cash flow from operating activities showed a net outflow of ¥52,841,683.43, contrasting with a net inflow of ¥57,873,864.42 in the prior period[20]. - The cash inflow from investment activities was ¥66,014,863.23, compared to a cash outflow of ¥22,214.61 in the previous period[20]. - The total cash inflow from financing activities reached 211,943,100.00 CNY, compared to 136,000,000.00 CNY in the same period last year, indicating a 55.8% increase[21]. - The net cash flow from financing activities was 18,082,296.41 CNY, a recovery from the previous year's negative cash flow of -96,660,240.95 CNY[21]. Inventory and Goodwill - The company reported a significant increase in inventory, which rose by 44.63% to ¥191,917,686.46 due to the acquisition of a subsidiary[8]. - The goodwill on the balance sheet reached ¥200,000,000.00, resulting from the acquisition of Jiangxi Deshipu Company[8]. - Inventory increased significantly to ¥191,917,686.46 from ¥132,696,240.18 at the beginning of the year, reflecting a growth of approximately 44.5%[15]. Research and Development - The company’s research and development expenses decreased by 71.50% to ¥3,138,082.33 compared to the previous year[9]. - Research and development expenses decreased to ¥3,138,082.33 from ¥11,010,052.54, reflecting a reduction of 71.5%[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,566[11]. - The largest shareholder, Jiangsu Suhua Group, holds 9.18% of shares, totaling 34,334,137 shares[11]. - The company has a significant amount of pledged shares, with 17,000,000 shares pledged by Hainan Jinsui International Holdings[11]. Other Financial Information - The company reported a financial asset impairment loss of ¥6,329,745.82, compared to a gain of ¥2,716,162.69 in the previous period[18]. - The company received government subsidies amounting to ¥4,810,265.53, an increase of 269.52% year-on-year[9]. - The company received 101,550,000.00 CNY from investment absorption in Q3 2022, reflecting strong investor confidence[21]. - The company paid 82,000,000.00 CNY in debt repayment during the quarter, down from 122,041,192.54 CNY in the same period last year[21]. - The company did not undergo an audit for the Q3 2022 report[22]. - The report was released by the board of directors on October 27, 2022[23].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥884,189,774.47, representing a 38.09% increase compared to ¥640,322,365.49 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached ¥2,457,615.73, a significant turnaround from a loss of ¥13,507,735.71 in the previous year, marking an increase of 118.19%[23]. - Basic and diluted earnings per share improved to ¥0.0070 from -¥0.0397, reflecting a 117.63% increase[23]. - The company's revenue for the reporting period reached ¥884.19 million, representing a 38.09% increase compared to ¥640.32 million in the same period last year[45]. - The company's revenue for the agricultural chemicals segment reached ¥823,779,589.65, representing a year-on-year increase of 28.65%[48]. - The gross profit margin for the agricultural chemicals segment decreased by 3.81% compared to the previous year, now standing at 4.77%[48]. - The company reported a total revenue of 1,440,815,000 CNY for the period, with a net profit of 199,948,300 CNY[65]. - The company reported a total comprehensive income of 1.1 billion yuan for the first half of 2022, reflecting a strong performance in its operations[182]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,117,506,622.68, up 22.54% from ¥1,727,949,962.51 at the end of the previous year[23]. - Total assets reached 2.12 billion yuan, up 22.54% from the previous year, while total liabilities increased by 36.44% to 1.45 billion yuan[37]. - The company's total assets increased to ¥2,292,564,650.66 as of June 30, 2022, up from ¥2,089,255,953.94 at the beginning of the year[162]. - Total liabilities increased to CNY 1,448,026,001.05 from CNY 1,061,312,988.31, marking a rise of about 36.4%[158]. - The total liabilities at the end of the current period are 1,098 million yuan, which is a decrease from 1,274 million yuan in the previous year, showing a reduction of approximately 14%[186]. Cash Flow - The net cash flow from operating activities was -¥46,181,038.45, a decline of 204.28% compared to ¥44,283,807.14 in the same period last year[23]. - The company reported a total cash and cash equivalents balance of ¥17,942,975.98 at the end of the first half of 2022, down from ¥140,497,478.41 at the end of the first half of 2021[172]. - The company experienced a net cash decrease of ¥15,024,050.46 in the first half of 2022, compared to a decrease of ¥86,297,489.79 in the first half of 2021[172]. - The cash outflow for financing activities totaled 152,776,767.41 CNY, which is an increase from 133,832,065.67 CNY in the prior period[174]. Research and Development - The company's R&D investment decreased by 68.03% to ¥2.27 million from ¥7.09 million due to capitalized expenditures on collaborative projects with research institutions[45]. - The company has allocated 44 million yuan for research and development in the first half of 2022, emphasizing its commitment to innovation[182]. - Research and development expenses decreased to ¥2,266,478.70 from ¥7,089,994.86 in the first half of 2021, a reduction of approximately 68%[165]. Market and Competition - The agricultural pesticide industry remains in a high prosperity phase, despite challenges from rising production costs and supply chain disruptions[31]. - The company is facing intense market competition in the pesticide industry, with many small manufacturers posing a challenge despite its strong production capacity and reliable product quality[67]. - To mitigate market competition risks, the company plans to accelerate technological upgrades, reduce costs, and expand into emerging markets[67]. - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[182]. Environmental and Safety Measures - The company has implemented a comprehensive waste gas treatment plan, achieving significant improvements in equipment integration, automation, and pipeline sealing[84]. - The company has made substantial investments in pollution control technologies, leading to a stable and continuous reduction in various pollutants[82]. - The company has established a hazardous waste temporary storage facility that meets the requirements of the Hazardous Waste Storage Pollution Control Standards[86]. - The company organized a total of 7 workshop-level drills and 1 hazardous waste special drill in the first half of 2022[88]. Shareholder and Stock Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company launched a stock incentive plan, granting up to 33.95 million restricted shares at a price of 3.00 CNY per share to attract and retain key talent[76]. - The stock incentive plan is designed to comply with relevant regulations and is expected to contribute positively to the company's long-term performance[133]. - The total number of restricted shares before the change is 25,670,446, representing 7.55% of the total shares[132]. Legal Matters - The company is involved in a lawsuit regarding performance compensation amounting to 62.5 million yuan, with ongoing enforcement proceedings[105]. - The company is pursuing a performance compensation of 55.02 million yuan due to a court ruling against a former employee[106]. - A court has ordered the immediate execution of a compensation amounting to 69 million yuan from a former employee's bank account[107]. - The company is involved in a legal dispute with Beijing Bochengli New Environment Technology Co., with a claim amount of 13.33 million yuan[108].